Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression
- PMID: 11585763
Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression
Abstract
Prostate cancer cells are generally resistant to apoptosis by conventional therapy. During a search for molecules that may overcome prostate cancer cell survival mechanisms, we identified the prostate apoptosis response-4 (Par-4) gene. Par-4 induced apoptosis of selective prostate cancer cells PC-3, DU-145, and TSU-Pr and caused tumor regression by inhibition of NF-kappaB activity and cell membrane trafficking of Fas and FasL that leads to the activation of the Fas-Fas-associated death domain-caspase-8 pro-death pathway. Neither Fas pathway activation alone nor inhibition of NF-kappaB activity with IkappaB-super repressor was sufficient to induce apoptosis of prostate cancer cells. Coregulation of these two pathways was essential and sufficient for Par-4 to induce apoptosis. On the other hand, prostate cancer cells LNCaP or normal prostatic epithelial cells that were resistant to apoptosis by Par-4 did not show Fas or FasL trafficking. These findings identify a mechanism of apoptosis by Par-4 and suggest that Par-4 may have therapeutic potential.
Similar articles
-
Antiapoptotic function of NF-kappaB in T lymphocytes is influenced by their differentiation status: roles of Fas, c-FLIP, and Bcl-xL.Cell Death Differ. 2003 Sep;10(9):1032-44. doi: 10.1038/sj.cdd.4401257. Cell Death Differ. 2003. PMID: 12934078
-
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.Cancer Res. 2006 May 1;66(9):4781-8. doi: 10.1158/0008-5472.CAN-05-3173. Cancer Res. 2006. PMID: 16651432
-
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.Cancer Res. 2003 Apr 1;63(7):1527-33. Cancer Res. 2003. PMID: 12670900
-
Apoptosis in prostate cancer: progressive and therapeutic implications (Review).Int J Mol Med. 2004 Jul;14(1):23-34. Int J Mol Med. 2004. PMID: 15202013 Review.
-
Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review).Int J Oncol. 2003 Jan;22(1):15-20. Int J Oncol. 2003. PMID: 12469180 Review.
Cited by
-
Phosphorylation of Par-4 by protein kinase A is critical for apoptosis.Mol Cell Biol. 2005 Feb;25(3):1146-61. doi: 10.1128/MCB.25.3.1146-1161.2005. Mol Cell Biol. 2005. PMID: 15657440 Free PMC article.
-
A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4.PLoS One. 2012;7(9):e44039. doi: 10.1371/journal.pone.0044039. Epub 2012 Sep 4. PLoS One. 2012. PMID: 22962598 Free PMC article.
-
Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death.FEBS Open Bio. 2014 Nov 21;5:8-19. doi: 10.1016/j.fob.2014.11.005. eCollection 2015. FEBS Open Bio. 2014. PMID: 25685660 Free PMC article.
-
Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity.Front Oncol. 2022 Mar 29;12:860446. doi: 10.3389/fonc.2022.860446. eCollection 2022. Front Oncol. 2022. PMID: 35425699 Free PMC article.
-
Arylquin 1 (Potent Par-4 Secretagogue) Inhibits Tumor Progression and Induces Apoptosis in Colon Cancer Cells.Int J Mol Sci. 2022 May 18;23(10):5645. doi: 10.3390/ijms23105645. Int J Mol Sci. 2022. PMID: 35628455 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous